Mdma molecule:

Image from PubChem

Mdma Clinical Trials


A Phase 1 Randomized, Double Blinded, Placebo-Controlled Single Dose and Repeat Dose Escalation Study to Evaluate Safety and Tolerability and Pharmacokinetic Characteristics of KDR2-2 in Adult Healthy Male and Female Volunteers


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04620109

Organisation Name: Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd

Overal Status: Recruiting

Start Date: August 26, 2020

Last Update: November 6, 2020

Lead Sponsor: Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd

Brief Summary: A Phase 1 randomized, double blinded, placebo-controlled, single dose escalation (SDE) and repeat dose escalation (RDE) study to evaluate safety and tolerability, and PK of KDR2-2 in healthy volunteers. The planned single dose levels are 0.03, 0.06, 0.12, and 0.24 mg/eye, and repeat dose levels are 0.06, 0.12, and 0.24 mg/eye, QID, × 6 days (one dose in the morning on Day 7). Subjects are randomized to KDR2-2 or placebo dosing (6:2 for SDE, or 8:2 for RDE) in each cohorts of relative dosing levels.

Conditions:
  • Corneal Neovascularization


Total execution time in seconds: 0.17110109329224